Piramal Pharma Ltd. is set to invest $90 million for expanding its manufacturing capabilities at two key US facilities, according to an exchange filing on Monday.
The expansion had been announced in connection with the 2025 SelectUSA Investment Summit.
This move directly addresses the increasing demand from US customers and the growing trend of onshoring drug supply. Through this investment, the company is betting on the benefits offered by US-based innovation.
The company is also employing brownfield expansions at its existing sites in Lexington, Kentucky, and Riverview, Michigan, utilising bank loans and internal accruals for an efficient capacity enhancement.
The expansion at the Lexington, Kentucky, facility, specialising in sterile compounding and injectable drug products, will introduce 24,000 sq ft of new manufacturing space alongside the laboratory.
This move will establish commercial-scale manufacturing for the company, with a scale-up in injectable drug products through the addition of a new filling line, two commercial-size lyophilizers, a specialised capping machine and an external vial washer, with operations expected to commence by late 2027.
The move follows US President Donald Trump's plans to order a cut in US prescription drug costs. This is expected to be achieved by mandating that Americans pay no more than people in countries that have the lowest price.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
